iQure Pharma is Drug Discovery in United States that focus on sodium-ion channel business. Founded in 2019. They cover business area such as operator, novel therapeutic, area, unmet medical need, a novel mode, action, chronic pain model, no sign, sedation, multitarget activity, pain relevant molecular target, calcium ion channel, sodium-ion channel, physician, new medical therapy, patient, an improved quality, life, illness.
2019
( 5 years old in 2024 )
Sodium-ion Channel
-
251 Little Falls Drive
Wilmington, DE 19808
United States
Private
operatornovel therapeuticareaunmet medical needa novel modeactionchronic pain modelno signsedationmultitarget activitypain relevant molecular targetcalcium ion channelsodium-ion channelphysiciannew medical therapypatientan improved qualitylifeillness
* We use standard office opening hours in near iQure Pharma's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
IQure Pharma is Drug Discovery business from United States that founded in 2019 (5 years old in 2024), iQure Pharma business is focusing on Sodium-ion Channel.
iQure Pharma headquarter office and corporate office address is located in 251 Little Falls Drive Wilmington, DE 19808 United States.
iQure Pharma was founded in United States.
In 2024, iQure Pharma is currently focus on sodium-ion channel sector.
Above is snippet of Google Trends for "sodium-ion channel" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with iQure Pharma, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
